NYSE:IBER Ibere Pharmaceuticals (IBER) Stock Price, News & Analysis → The 1,000X Crypto Playbook (From True Market Insiders) (Ad) Free IBER Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.18▼$10.1850-Day Range$10.15▼$10.2152-Week Range$9.74▼$10.75Volume44,499 shsAverage Volume110,000 shsMarket Capitalization$175.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Ibere Pharmaceuticals alerts: Email Address Ad True Market Insiders#1 Crypto of 2024Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Ibere Pharmaceuticals Stock (NYSE:IBER)Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.Read More Ad True Market Insiders#1 Crypto of 2024Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 IBER Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive IBER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ibere Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNYSE:IBER CUSIPN/A CIK1835205 Webwww.iberepharma.com Phone267-765-3222FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-83.01% Return on Assets4.47% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.09 per share Price / Cash Flow112.42 Book Value($0.63) per share Price / Book-16.16Miscellaneous Outstanding Shares17,250,000Free Float13,800,000Market Cap$175.61 million OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Osagie O. Imasogie Esq. (Age 61)Chairman & CEO Ms. Lisa M. Gray CPA (Age 58)CPA, CVA, CFO, Exec. VP & Director Mr. Zoltan Kerekes J.D. (Age 57)COO, Exec. VP & Director Key CompetitorsARYA Sciences Acquisition Corp IVNASDAQ:ARYDFuture Health ESGNASDAQ:FHLTenGeneNASDAQ:ENGNVaxartNASDAQ:VXRTOrchestra BioMedNASDAQ:OBIOView All Competitors This page (NYSE:IBER) was last updated on 4/17/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe 1,000X Crypto PlaybookTrue Market InsidersSecret Bull Market Starts in This Unusual SectorAltimetryHe Is Giving Away BitcoinCrypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ibere Pharmaceuticals Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.